Blog | Veristat Insightful Perspectives

Regulatory Guidance Monthly Review - September 2019

September 2019 Updates from FDA 


Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.   Below are the relevant links to updates provided in September 2019.

 

Read More

What Matters Most in the Clinical Study Feasibility Process

From  Site Selection to Protocol Development: A Thorough Approach to the Feasibility Process

Read More

Regulatory Guidance Monthly Review - August 2019

August 2019 Updates from FDA 


Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.   Below are the relevant links to updates provided in August 2019.

 

Read More

Regulatory Guidance Monthly Review - July 2019

July 2019 Updates from FDA 


Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.   Below are the relevant links to updates provided in July 2019.

 

Read More

Regulatory Guidance Monthly Review - June 2019

June 2019 Updates from FDA 


Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.   Below are the relevant links to updates provided in June 2019.

 

Read More

Regulatory Guidance Review - May 2019

May 2019 Updates from FDA 


Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  and European Medicines Agency (EMA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.   Below are the relevant links to updates provided in May 2019.

 

Read More

Regulatory Guidance Review - April 2019

Latest Updates from FDA & EMA

April 2019 Updates

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  and European Medicines Agency (EMA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.   Below are the relevant links to updates provided in April 2019.

 

Read More

5 Ways To Transform Your Work Space For Inspiration and Creativity


Person at Desk UninspiredPicture this: it’s mid-afternoon on a Thursday, and you’re at your desk. You have important work to do, but your attention is wandering, and you can’t seem to get the motivation you need to get anything done.

Read More

Regulatory Guidance Review

Latest Updates from FDA & EMA

March 2019

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  and European Medicines Agency (EMA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval.   Below are the relevant links to updates provided in March 2019.

Read More

5 Best Practices for Making Virtual Teams Work

At Veristat our need to manage and work in virtual environments continues to increase. With six offices globally and nearly 300 employees, we are building teams with members spread out in different physical locations. Our geographically dispersed teams continue to grow with our increasing remote employee population; In fact remote workers are our largest growing population with nearly 30 % of our employees working from their home offices.

Read More